Peroxisome proliterator-activated receptor γ inhibits follicular and anaplastic thyroid carcinoma cells growth by upregulating p21 Cip1/WAF1 gene in a Sp1-dependent manner

Endocrine-Related Cancer

Volumn 15, Issue 2, 2008, Pages 545-557

  Bonofiglio, D ^a   Qi, H ^a   Gabriele, S ^a   Catalano, S ^a   Aquila, S ^a   Belmonte, M ^a   Ando S ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ANTISENSE OLIGONUCLEOTIDE; CYCLIN DEPENDENT KINASE INHIBITOR 1; HISTONE H3; MITHRAMYCIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN P53; RNA POLYMERASE II; ROSIGLITAZONE; TRANSCRIPTION FACTOR SP1; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A;

ACETYLATION; ANAPLASTIC CARCINOMA; ARTICLE; CANCER INHIBITION; CHROMATIN IMMUNOPRECIPITATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FOLLICULAR CARCINOMA; GEL MOBILITY SHIFT ASSAY; GENE CONTROL; GENE SILENCING; HUMAN; HUMAN CELL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN METHYLATION; RNA INTERFERENCE; THYROID CARCINOMA; THYROID FOLLICLE CELL; TRANSCRIPTION INITIATION; TRANSIENT TRANSFECTION; UPREGULATION; ADENOCARCINOMA; CELL DIVISION; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; THYROID TUMOR; TUMOR CELL LINE;

ADENOCARCINOMA, FOLLICULAR; CELL DIVISION; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOGLYCEMIC AGENTS; OLIGONUCLEOTIDES, ANTISENSE; PPAR GAMMA; PROMOTER REGIONS (GENETICS); SIGNAL TRANSDUCTION; SP1 TRANSCRIPTION FACTOR; THIAZOLIDINEDIONES; THYROID NEOPLASMS; UP-REGULATION;

EID: 45849154277     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/ERC-07-0272     Document Type: Article

References (57)

1. Aiello A, Pandini G, Frasca F, Conte E, Murabito A, Sacco A, Genua M, Vigneri R & Belfiore A 2006 Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells. Endocrinology 147 4463-4475.
2. Ain KB 1998 Anaplastic thyroid carcinoma: behaviour, biology, and therapeutic approaches. Thyroid 8 715-726.
3. Andrews NC & Faller DV 1991 A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Research 19 2499.
4. Auwerx J 1999 PPARγ, the ultimate thrifty gene. Diabetologia 42 1033-1049.
5. Blume SW, Snyder RC, Ray R, Thomas S, Koller CA & Miller DM 1991 Mithramycin inhibits SP1 binding and selectively inhibits transcriptional activity of the dihydrofolate reductase gene in vitro and in vivo. Journal of Clinical Investigations 88 1613-1621.
6. Bonofiglio D, Gabriele S, Aquila S, Catalano S, Gentile M, Middea E, Giordano F & Ando S 2005 Estrogen receptor alpha binds to peroxisome proliferator-activated receptor response element and negatively interferes with peroxisome proliferator-activated receptor gamma signaling in breast cancer cells. Clinical Cancer Research 11 6139-6147.
7. Bonofiglio D, Aquila S, Catalano S, Gabriele S, Belmonte M, Middea E, Qi H, Morelli C, Gentile M, Maggiolini M et al. 2006 Peroxisome proliferator-activated receptor-gamma activates p53 gene promoter binding to the nuclear factor-kappaB sequence in human MCF7 breast cancer cells. Molecular Endocrinology 20 3083-3092.
8. Bourdon JC 2007 p53 and its isoforms in cancer. British Journal of Cancer 97 277-282.
9. Chen Y, Wang SM, Wu JC & Huang SH 2006 Effects of PPARgamma agonists on cell survival and focal adhesions in a Chinese thyroid carcinoma cell line. Journal of Cellular Biochemistry 98 1021-1035.
10. Chung SH, Onoda N, Ishikawa T, Ogisawa K, Takenaka C, Yano Y, Hato F & Hirakawa K 2002 Peroxisome proliferator-activated receptor gamma activition induce cell cycle arrest via p53-indipendent pathway in human anaplastic thyroid cancer cells. Japanese Journal of Cancer Research 93 1358-1365.
11. Clay CE, Namen AM, Atsumi G, Willingham MC, High KP, Kute TE, Trimboli AJ, Fonteh AN, Dawson PA & Chilton FH 1999 Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells. Carcinogenesis 20 1905-1911.
12. Copland JA, Marlow LA, Kurakata S, Fujiwara K, Wong AK, Kreinest PA, Williams SF, Haugen BR, Klopper JP & Smallridge RC 2006 Novel high-affinity PPARγ agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene 25 2304-2317.
13. Deng T, Shan S, Li PP, Shen ZF, Lu XP, Cheng J & Ning ZQ 2006 Peroxisome proliferator-activated receptor-gamma transcriptionally up-regulates hormone-sensitive lipase via the involvement of specificity protein-1. Endocrinology 147 875-884.
14. Desvergne B & Wahli W 1999 Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocrine Reviews 20 649-688.
15. Donghi R, Longoni A, Pilotti S, Michieli P, Della Porta G & Pierotti MA 1993 P53 mutation are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. Journal of Clinical Investigations 91 1753-1760.
16. el-Diery WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW & Vogelstein B 1993 WAF1, a potential mediator of p53 tumor suppression. Cell 75 817-825.
17. Elstner E, Mueller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D & Koeffler HP 1998 Ligands for peroxisome proliferator-activated receptor gamma and reinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. PNAS 95 8806-8811.
18. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH & Koeffler HP 1993 High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. Journal of Clinical Investigations 91 179-184.
19. Fang Z, Fu Y, Liang Y, Li Z, Zhang W, Jin J, Yang Y & Zha X 2007 Increased expression of integrin beta1 subunit enhances p21WAF1/Cip1 transcription through the Sp1 sites and p300-mediated histone acetylation in human hepatocellular carcinoma cells. Journal of Cellular Biochemistry 101 654-664.
20. Flück CE & Miller WL 2004 GATA-4 and GATA-6 modulate tissue-specific transcription of the human gene for P450c17 by direct interaction with Sp1. Molecular Endocrinology 18 1144-1157.
21. Han S, Sidell N, Fisher BP & Roman J 2004 Up-regulation of p21 gene expression by peroxisome proliferator-activated receptor γin human lung carcinoma cells. Clinical Cancer Research 10 1911-1919.
22. He H & Lehming N 2003 Global effects of histone modifications. Briefings in Functional Genomics & Proteomics 2 234-243.
23. Hilton TL & Wang EH 2003 Transcription factor IID recruitment and Sp1 activation. Dual function of TAF1 in cyclin D1 transcription. Journal of Biological Chemistry 278 12992-13002.
24. Hong J, Samudio I, Liu S, Abdelrahim M & Safe S 2004 Peroxisome proliferator-activited receptor γ- dependent activation of p21 in panc-28 pancreatic cancer cells involves Sp1 and Sp4 proteins. Endocrinology 145 5774-5785.
25. Husmann M, Dragneva Y, Romahn E & Jehnichen P 2000 Nuclear receptors modulate the interaction of Sp1 and GC-rich DNA via ternary complex formation. Biochemical Journal 352 763-772.
26. Ito T, Seyama T, Mizuno T, Tsuyama N, Hayashi T & Hayashi Y 1992 Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of thyroid gland. Cancer Research 52 1369-1371.
27. Jiang H, Lin J, Su ZZ, Collart FR, Huberman E & Fisher PB 1994 Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in absence of p53. Oncogene 9 3397-3406.
28. Klopper JP, Hays WR, Sharma V, Baumbusch MA, Hershman JM & Haugen BR 2004 Retinoid X receptor-gamma and peroxisome proliferator-activated receptor-gamma expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment. Molecular Cancer Therapeutics 3 1011-1020.
29. Kondo T, Ezzat S & Asa SL 2006 Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nature Reviews. Cancer 6 292-306.
30. Kuboto T, Koshizuka K, Williamson IA, Asou H, Said JW, Holden S, Miyoshi I & Koeffler HP 1998 Ligand of peroxisome proliferator-activated receptor gamma (rosiglitazone) has potent anti-tumor effects agonist human prostate cancer both in vitro and in vivo. Cancer Research 58 3344-3352.
31. Li Y, Jenkins CW, Nichols MA & Xiong Y 1994 Cell cycle expression and p53 regulation of cyclin-dependent kinase inhibitor p21. Oncogene 9 2261-2268.
32. Li D, Mitchell D, Luo J, Yi Z, Cho SG, Guo J, Li X, Ning G, Wu X & Liu M 2007 Estrogen regulates KiSS1 gene expression through estrogen receptor alpha and SP protein complexes. Endocrinology 148 4821-4828.
33. Liu S, Semenciw R, Ugnat AM & Mao Y 2001 Increasing thyroid cancer incidence in Canada, 1970-1996: time trends and age-period-cohort effects. British Journal of Cancer 85 1335-1339.
34. Maggiolini M, Donzè O & Picard D 1999 A non-radioactive method for inexpensive quantitative RT-PCR. Biological Chemistry 380 695-697.
35. Martelli ML, Iuliano R, Le Pera I, Samà I, Monaco C, Cammarota S, Kroll T, Chiariotti L, Santoro M & Fusco A 2002 Inhibitory effects of peroxisome proliferator-activated receptor gammaon thyroid carcinoma cell growth. Journal of Clinical Endocrinology and Metabolism 87 4728-4735.
36. Moon SK, Choi YH, Kim CH & Choi WS 2006 p38MAPK mediates benzyl isothiocyanate-induced p21WAF1 expression in vascular smooth muscle cells via the regulation of Sp1. Biochemical and Biophysical Research Communications 350 662-668.
37. Mueller E, Sarrf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Flecher C, Singer S & Spiegelman BM 1998 Terminal differentiation of human breast cancer through PPARγ. Molecular Cell 1 465-470.
38. Nakamura T, Yana I, Kobayashi T, Shin E, Karakawa K, Fujita S, Miya A, Mori T, Nishisho I & Takai S 1992 P53 gene mutations associated with anaplastic transformation of human thyroid carcinomas. Japanese Journal of Cancer Research 83 1293-1298.
39. Noé V, Alemany C, Chasin LA & Ciudad CJ 1998 Retinoblastoma protein associates with SP1 and activates the hamster dihydrofolate reductase promoter. Oncogene 16 1931-1938.
40. Ohta K, Endo T, Haraguchi K, Hershman JM & Onaya T 2001 Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. Journal of Clinical Endocrinology and Metabolism 86 2170-2177.
41. Panno ML, Mauro L, Marsico S, Bellizzi D, Rizza P, Morelli C, Salerno M, Giordano F & Andò S 2006 Evidence that the mouse insulin receptor substrate-1 belongs to the gene family on which the promoter is activated by estrogen receptor alpha through its interaction with Sp1. Journal of Molecular Endocrinology 36 91-105.
42. Park JW, Jang MA, Lee YH, Passaniti A & Kwon TK 2001 p53-independent elevation of p21 expression by PMA results from PKC-mediated mRNA stabilization. Biochemical and Biophysical Research Communications 280 244-248.
43. Parkin DM, Bray F, Ferlay J & Pisani P 2005 Global cancer statistics, 2002. CA: A Cancer Journal for Clinicians 55 74-108.
44. Pipaón C, Tsai SY & Tsai MJ 1999 COUP-TF upregulates NGFI-A gene expression through an Sp1 binding site. Molecular and Cellular Biology 19 2734-2745.
45. Rice JC, Briggs SD, Ueberheide B, Barber CM, Shabanowitz J, Hunt DF, Shinkai Y & Allis CD 2003 Histone methyltransferases direct different degrees of methylation to define distinct chromatin domains. Molecular Cell 12 1591-1598.
46. Rotheneder H, Geymayer S & Haidweger E 1999 Transcription factors of the Sp1 family: interaction with E2F and regulation of the murine thymidine kinase promoter. Journal of Molecular Biology 293 1005-1015.
47. Sassa Y, Hata Y, Aiello LP, Taniguchi Y, Kohno K & Ishibashi T 2004 Bifunctional properties of peroxisome proliferator-activated receptor gamma 1 in KDR gene regulation mediated via interaction with both Sp1 and Sp3. Diabetes 53 1222-1229.
48. Scarpulla RC 2002 Transcriptional activators and reactivators in the nuclear control of mitochondrial function in mammalian cells. Gene 286 81-89.
49. Teferedegne B, Green MR, Guo Z & Boss JM 2006 Mechanism of action of a distal NF-κB-dependent enhancer. Molecular and Cellular Biology 26 5759-5770.
50. Tian H, Wittmack EK & Jorgensen TJ 2000 p21WAF1/CIP1 antisense therapy radiosensitizes human colon carcinoma by converting growth arrest to apoptosis. Cancer Research 60 679-684.
51. Tontonoz P, Singer S, Forman BM, Sarraf P, Fletcher JA, Flechter CD, Brun RP, Mueller E, Altiok S, Oppenheim H et al. 1997 Terminal differentiation of human liposarcoma cells induce by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. PNAS 94 237-241.
52. Tseng L, Tang M, Wang Z & Mazella J 2003 Progesterone receptor (hPR) upregulates the fibronectin promoter activity in human decidual fibroblasts. DNA and Cell Biology 22 633-640.
53. Tvrdík D, Dundr P, Povýsil C, Pytlík R & Planková M 2006 Up-regulation of p21WAF1 expression is mediated by Sp1/Sp3 transcription factors in TGFβ1-arrested malignant B cells. Medical Science Monitor 12 227-234.
54. Vousden KH & Lu X 2002 Live or let die: the cell's response to p53. Nature Reviews. Cancer 2 594-604.
55. Weiss RH, Marshall D, Howard L, Corbacho AM, Cheung AT & Sawai ET 2003 Suppression of breast carcinoma growth and angiogenesis by an antisense oligodeoxynucleotide to p21 (WAF1/CIP1). Cancer Letters 189 39-48.
56. Wu RC & Schonthal AH 1997 Activation of p53-p21waf1 pathway in response to disruption of cell-matrix interactions. Journal of Biological Chemistry 272 29091-29098.
57. Zhang C, Shin DJ & Osborne TF 2005 A simple promoter containing two Sp1 sites controls the expression of sterol-regulatory-element-binding protein 1a (SREBP-1a). Biochemical Journal 386 161-168.